Integra LifeSciences Holdings Corporation acquired 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.
April 31, 2024
Share
Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million on December 12, 2023. The consideration consists of $275 million in cash at closing, subject to customary purchase price adjustments, and an additional $5 million upon the achievement of certain regulatory milestones. The acquisition will become part of Integra?s Codman Specialty Surgical (CSS) division. The transaction expected to be accretive to Integra?s long-range plan. The transaction, subject to customary closing conditions and regulatory approvals and antitrust approvals, is expected to close by the second quarter of 2024. Following the close, transition services, including transition manufacturing services, will be provided for up to four years. For the year ending 2022, Acclarent reported $110 million revenue. Goldman, Sachs & Co. is serving as exclusive financial advisor and Morgan, Lewis & Bockius LLP is acting as legal advisor to Integra.
Integra LifeSciences Holdings Corporation (NasdaqGS:IART) acquired 100% stake in Acclarent, Inc. from Ethicon US, LLC on April 1, 2024.
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.